Concomitant Kinase-Dead BRAF and Oncogenic KRAS Lead to an Aggressive Biologic Behavior and Tumor Lysis Syndrome: A...

Area of Science:

• Oncology
• Genetics
• Gastroenterology

Background:

• Tumor lysis syndrome (TLS) is a rare but severe oncological emergency, typically associated with hematological malignancies and rapidly proliferating tumors.
• KRAS and BRAF mutations are crucial oncogenes in the MAPK pathway, often assessed for predicting anti-EGFR therapy resistance in gastrointestinal (GI) cancers.
• Concomitant KRAS and BRAF mutations in GI tumors are exceptionally rare, found in less than 0.001% of cases, and linked to aggressive tumor phenotypes.

Observation:

• This report details an unusual case of a young male patient with locally advanced duodenal mucinous adenocarcinoma.
• The patient's tumor harbored concomitant KRAS and BRAF mutations, a rare genetic profile.
• This unique mutation profile led to significant hyperactivation of the Epidermal Growth Factor Receptor (EGFR) signaling pathway.

Findings:

• The patient developed TLS within a day of initiating the mFOLFOX-6 chemotherapy regimen.
• High-volume hydration was effective in achieving clinical resolution of the TLS.
• Despite initial management of TLS, the patient unfortunately passed away 10 days later during anesthesia induction.

Implications:

• This case underscores the potential for TLS in solid tumors with specific rare genetic profiles, even with standard chemotherapy.
• The aggressive nature associated with concomitant KRAS and BRAF mutations warrants careful monitoring and consideration of tailored therapeutic strategies.
• Further research into the management of TLS in rare solid tumor presentations and the impact of combined mutations on treatment outcomes is crucial.